Mannatech, (MTEX) Reaches $19.70 After 4.00% Up Move; Altiris (ATRS)’s Sentiment Is 1.16

May 18, 2018 - By Winifred Garcia

Mannatech, Incorporated (NASDAQ:MTEX) Logo

The stock of Mannatech, Incorporated (NASDAQ:MTEX) is a huge mover today! The stock increased 23.90% or $3.8 during the last trading session, reaching $19.7. About 151,633 shares traded or 1232.57% up from the average. Mannatech, Incorporated (NASDAQ:MTEX) has risen 0.47% since May 18, 2017 and is uptrending. It has underperformed by 11.08% the S&P500.The move comes after 8 months positive chart setup for the $53.57M company. It was reported on May, 18 by Barchart.com. We have $20.49 PT which if reached, will make NASDAQ:MTEX worth $2.14M more.

Altiris Inc (ATRS) investors sentiment decreased to 1.16 in 2017 Q4. It’s down -0.13, from 1.29 in 2017Q3. The ratio is negative, as 44 investment managers increased or started new stock positions, while 38 reduced and sold their holdings in Altiris Inc. The investment managers in our database now hold: 54.49 million shares, up from 53.56 million shares in 2017Q3. Also, the number of investment managers holding Altiris Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 9 Reduced: 29 Increased: 25 New Position: 19.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $404.61 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

The stock decreased 0.39% or $0.01 during the last trading session, reaching $2.58. About 161,248 shares traded. Antares Pharma, Inc. (ATRS) has declined 23.10% since May 18, 2017 and is downtrending. It has underperformed by 34.65% the S&P500.

More news for Antares Pharma, Inc. (NASDAQ:ATRS) were recently published by: Globenewswire.com, which released: “Antares Pharma Reports First Quarter 2018 Operating and Financial Results” on May 08, 2018. Seekingalpha.com‘s article titled: “Antares Pharma’s (ATRS) CEO Robert Apple on Q1 2018 Results – Earnings Call Transcript” and published on May 08, 2018 is yet another important article.

Since January 1, 0001, it had 0 insider buys, and 3 sales for $1.72 million activity.

Jw Asset Management Llc holds 3.98% of its portfolio in Antares Pharma, Inc. for 1.88 million shares. Armistice Capital Llc owns 7.60 million shares or 1.51% of their US portfolio. Moreover, Broadfin Capital Llc has 1.48% invested in the company for 4.54 million shares. The Minnesota-based Perkins Capital Management Inc has invested 0.48% in the stock. Perceptive Advisors Llc, a New York-based fund reported 3.75 million shares.

Analysts await Antares Pharma, Inc. (NASDAQ:ATRS) to report earnings on August, 14. They expect $-0.02 EPS, 0.00% or $0.00 from last year’s $-0.02 per share. After $-0.04 actual EPS reported by Antares Pharma, Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

Mannatech, Incorporated operates as a wellness solution provider. The company has market cap of $53.57 million. It develops and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It currently has negative earnings. The firm markets its products through network marketing channel in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific.

More important recent Mannatech, Incorporated (NASDAQ:MTEX) news were published by: Streetinsider.com which released: “Mannatech (MTEX) to Commence Cash Tender Offer to Purchase up to $16M of Its Common Stock” on May 17, 2018, also Benzinga.com published article titled: “Mid-Morning Market Update: Markets Mixed; Deere Misses Q2 Estimates”, Seekingalpha.com published: “Mannatech, Inc. (MTEX) CEO Al Bala on Q1 2018 Results – Earnings Call Transcript” on May 12, 2018. More interesting news about Mannatech, Incorporated (NASDAQ:MTEX) was released by: Businesswire.com and their article: “Mannatech Introduces Industry’s First Three-in-One Fitness Drink Mix, EMPACT+â„¢” with publication date: May 16, 2018.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>